Cellosaurus logo
expasy logo

Cellosaurus HCC1419/TDR (CVCL_B3ML)

[Text version]
Cell line name HCC1419/TDR
Accession CVCL_B3ML
Resource Identification Initiative To cite this cell line use: HCC1419/TDR (RRID:CVCL_B3ML)
Comments Selected for resistance to: DrugBank; DB05773; Trastuzumab emtansine (T-DM1).
Derived from site: In situ; Breast; UBERON=UBERON_0000310.
Sequence variations
  • Mutation; HGNC; HGNC:11998; TP53; Simple; p.Ala74fs*47 (c.220_226delGCCCCTG); Zygosity=Heterozygous (from parent cell line).
  • Mutation; HGNC; HGNC:11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Heterozygous (from parent cell line).
Disease Breast ductal carcinoma (NCIt: C4017)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_1251 (HCC1419)
Sex of cell Female
Age at sampling 42Y
Category Cancer cell line
Publications

CLPUB00650
Sabbaghi Mehrjardi M.A.
Uncovering mechanisms of acquired resistance to trastuzumab-emtansine (T-DM1) in HER2 positive breast cancer.
Thesis PhD (2017); Universitat de Barcelona; Barcelona; Spain

PubMed=28821558; DOI=10.1158/1078-0432.CCR-17-0696
Sabbaghi Mehrjardi M.A., Gil-Gomez G., Guardia C., Servitja S., Arpi O., Garcia-Alonso S., Menendez S., Arumi-Uria M., Serrano L., Salido M., Muntasell A., Martinez-Garcia M., Zazo S., Chamizo C., Gonzalez-Alonso P., Madoz-Gurpide J., Eroles P., Arribas J., Tusquets I., Lluch A., Pandiella A., Rojo F., Rovira A., Albanell J.
Defective cyclin B1 induction in trastuzumab-emtansine (T-DM1) acquired resistance in HER2-positive breast cancer.
Clin. Cancer Res. 23:7006-7019(2017)

Cross-references
Cell line databases/resources cancercelllines; CVCL_B3ML
Encyclopedic resources Wikidata; Q110432839
Entry history
Entry creation16-Dec-2021
Last entry update19-Dec-2024
Version number6